Detail

Study ID: NRN Darbepoetin Study

Title:

Darbepoetin Trial to Improve Red Cell Mass and Neuroprotection in Preterm Infants

Description:
Title: Darbepoetin Trial to Improve Red Cell Mass and Neuroprotection in Preterm Infants Description: This study is looking at a medication called darbepoietin alfa (Darbe) and includes infants who were 23-28 weeks at birth. This study is looking at the effects of Darbe on new red blood cell growth, the number of blood transfusions needed while in the hospital and development at around 2 years of age.
Location:
Sioux Falls Region
Principal Investigator:
Michelle Baack, MD
Disease:
Brain and Nervous System
Stage:
Unknown
Status:
Active - Open to Accrual